RESUMO
Late-onset neutropaenia is defined as an absolute neutrophil count of <1.5×103cells/µL starting>4 weeks after the last dose of rituximab, in the absence of other identifiable causes. Late-onset neutropaenia is a rare adverse reaction to rituximab (observed in approximately 5% of patients). Rheumatic diseases constitute the main indication for rituximab; in these patients, neutropaenia appears after a mean of>28 days. Ocrelizumab is another monoclonal antibody that binds to CD20 (a glycosylated phosphoprotein mainly expressed on the membranes of B-lymphocytes); in January 2018, it was approved for the treatment of relapsing-remitting and primary progressive multiple sclerosis. We present a case of neutropaenia following intravenous infusion of ocrelizumab in a patient with primary progressive multiple sclerosis who presented with neutropaenic fever, herpetic stomatitis, and ecthyma gangrenosum only 20 days after infusion.
Assuntos
Esclerose Múltipla Crônica Progressiva , Esclerose Múltipla , Neutropenia , Humanos , Esclerose Múltipla/tratamento farmacológico , Rituximab/efeitos adversosRESUMO
Late-onset neutropaenia is defined as an absolute neutrophil count of <1.5 × 103 cells/μL starting > 4 weeks after the last dose of rituximab, in the absence of other identifiable causes.Late-onset neutropaenia is a rare adverse reaction to rituximab (observed in approximately 5% of patients). Rheumatic diseases constitute the main indication for rituximab; in these patients, neutropaenia appears after a mean of > 28 days.Ocrelizumab is another monoclonal antibody that binds to CD20 (a glycosylated phosphoprotein mainly expressed on the membranes of B-lymphocytes); in January 2018, it was approved for the treatment of relapsing-remitting and primary progressive multiple sclerosis.We present a case of neutropaenia following intravenous infusion of ocrelizumab in a patient with primary progressive multiple sclerosis who presented with neutropaenic fever, herpetic stomatitis, and ecthyma gangrenosum only 20 days after infusion.(AU)
La neutropenia de aparición tardía se define como un recuento absoluto de neutrófilos < 1,5 × 103/μl que se produce > 4 semanas después de la última dosis de rituximab, precedido por un recuento de neutrófilos normal y sin otra causa identificable. Es una complicación rara del tratamiento con rituximab, habiéndose observado en aproximadamente el 5% de los pacientes tratados, siendo las enfermedades reumáticas su principal indicación, con un tiempo medio hasta el desarrollo de la neutropenia de al menos 28 días. El ocrelizumab, al igual que el rituximab, es un anticuerpo monoclonal dirigido a CD20, una fosfoproteína glicosilada de membrana que se encuentra predominantemente en los linfocitos B y que se aprobó en enero de 2018 para el tratamiento de la esclerosis múltiple remitente recurrente y la esclerosis múltiple progresiva primaria. Se describe un caso de neutropenia después de la infusión de ocrelizumab en un paciente con esclerosis múltiple progresiva primaria que presentó neutropenia febril, estomatitis herpética y ectima gangrenoso solo 20 días después de la infusión.(AU)
Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Esclerose Múltipla/diagnóstico , Esclerose Múltipla/tratamento farmacológico , Neutropenia/tratamento farmacológico , Anticorpos Monoclonais , Estomatite Herpética , Neutropenia Febril , Pacientes Internados , Exame Físico , Neurologia , Doenças do Sistema NervosoAssuntos
Humanos , Masculino , Idoso , Síndrome das Unhas Amareladas/diagnóstico , Doenças LinfáticasRESUMO
Chronic histiocytic intervillositis (CHIV) is an uncommon condition, characterized by an infiltrate of mononuclear cells of maternal origin in the intervillous space that has been related to placenta insufficiency and poor perinatal outcomes. The aetiology is unclear, although maternal immunological aggression toward fetal tissues has been proposed. Dermatomyositis (DM) is a multisystem autoimmune inflammatory myopathy. Different autoantibodies have been associated with particular clinical phenotypes; presence of anti-melanoma differentiation-associated gen 5 (MDA5) antibody has been associated with rapidly progressive interstitial lung disease and severe skin lesions, none of which the woman had. Described here is a case of a woman diagnosed with amyopathic DM with positive anti-MDA5 antibodies after two intrauterine fetal deaths. Pathological examination of the placenta in both pregnancies showed CHIV. The presence of a potential relationship between both processes is discussed.
Assuntos
Doenças da Unha , Unhas Malformadas , Derrame Pleural , Humanos , Doenças da Unha/diagnóstico , Unhas , SíndromeRESUMO
COVID-19 has rarely been associated with immune-mediated phenomena such as autoimmune haemolytic anaemia (AIHA). Both cold hemolysis with cold agglutinin detection and warm haemolysis have been described with variable prognoses. Current treatment regimens are based on experience with other case series and case reports, which still represent a clinical challenge. Corticosteroids, red cell transfusions and rituximab have been successfully employed. We present 3 cases of AIHA in the context of COVID-19 disease, the first case successfully treated with plasma exchange and long-term follow-up of the 3 cases showing complete remission of anaemia.
RESUMO
Late-onset neutropaenia is defined as an absolute neutrophil count of <1.5×103cells/µL starting>4 weeks after the last dose of rituximab, in the absence of other identifiable causes. Late-onset neutropaenia is a rare adverse reaction to rituximab (observed in approximately 5% of patients). Rheumatic diseases constitute the main indication for rituximab; in these patients, neutropaenia appears after a mean of>28 days. Ocrelizumab is another monoclonal antibody that binds to CD20 (a glycosylated phosphoprotein mainly expressed on the membranes of B-lymphocytes); in January 2018, it was approved for the treatment of relapsing-remitting and primary progressive multiple sclerosis. We present a case of neutropaenia following intravenous infusion of ocrelizumab in a patient with primary progressive multiple sclerosis who presented with neutropaenic fever, herpetic stomatitis, and ecthyma gangrenosum only 20 days after infusion.
RESUMO
INTRODUCTION: Anti-Ro/SSA and anti-La/SSB antibodies are associated with neonatal lupus and congenital heart block. Controversial results regarding perinatal outcomes are found and less is known about aneuploidy screening. The hypothesis is that the presence of anti-Ro and/or anti-La antibodies influences the levels of PAPP-A and ß-HCG, thus interfering in the calculation of risk of aneuploidies. MATERIAL AND METHODS: Fifty-five anti-Ro/SSA positive pregnant women were included. The demographic characteristics and laboratory variables were studied. Data concerning chromosomopaties screening were also recorded. RESULTS: PAPP-A and ß-HCG levels were calculated (as well as NT and CRL) and compared with a healthy cohort of 12971 pregnant women. PAPP-A levels in mg/mL were lower significatively. In anti-La/SS-B cohort, significant differences were found in PAPP-A in mg/mL and in MoM. Combined risks for Down syndrome (DS) in both groups were higher but the differences were due to age. CONCLUSIONS: Serum levels of PAPP-A were significative lower but not confirmed when adjusted to MoM. This will have to be confirmed in studies with a larger number of patients and to check whether there is an impact in the calculation of DS risk or not. They could represent a group of pregnant women with significantly a higher risk of adverse perinatal outcome. Key Points ⢠Pregnant patients with anti-Ro/SS-A ant/or anti-La/SS-B antibodies have low PAPP-A levels compared with pregnant women without antibodies. ⢠PAPP-A levels are used in obstetrics for aneuploidies screening in the first trimester, so in these patients, there could be more false positive screening. ⢠In these findings are verified in trials with a larger number of patients, a correction variable would have to be applied for the aneuploidies screening calculation. ⢠Also, low PAPP-A levels are correlated with poor placentation, that is to say, more risk of miscarriages, small fetus for gestational age, and preeclampsia. This is another topic to take into consideration in this population.
Assuntos
Gonadotropina Coriônica Humana Subunidade beta , Gestantes , Aneuploidia , Biomarcadores , Feminino , Humanos , Recém-Nascido , Gravidez , Primeiro Trimestre da Gravidez , Proteína Plasmática A Associada à GravidezAssuntos
Doença Granulomatosa Crônica , Corticosteroides/uso terapêutico , Antibacterianos/uso terapêutico , Antifúngicos/uso terapêutico , Infecções Bacterianas/diagnóstico , Infecções Bacterianas/tratamento farmacológico , Infecções Bacterianas/etiologia , Infecções Bacterianas/genética , Criança , Pré-Escolar , Feminino , Doença Granulomatosa Crônica/complicações , Doença Granulomatosa Crônica/diagnóstico , Doença Granulomatosa Crônica/genética , Doença Granulomatosa Crônica/terapia , Humanos , Imunossupressores/uso terapêutico , Imunoterapia , Lactente , Masculino , Mutação , Micoses/diagnóstico , Micoses/tratamento farmacológico , Micoses/etiologia , Micoses/genética , NADPH Oxidase 2/genética , NADPH Oxidases/genética , EspanhaRESUMO
Respiratory viriasis are acute infectious diseases with a usually favorable course. Influenza is the disease caused by influenza viruses A and B; it could cause seasonal periodical epidemics and influenza A is implicated in worlwide pandemias. Influenza complications usually are limited to older patients and to those with comorbilities, especially those with chronic respiratory or cardiovascular diseases. Anti-influenza therapy has an effect on the duration of the symptomatic period and vaccination efficiently decreases the incidence of the infection. Respiratory syncytial virus is the more frequent cause of the acute bronchiolitis in breastfeeding patients. Rinovirus and coronavirus are implicated in the common cold. Coronavirus was the etiological agent of the severe acute respiratory syndrome, described in 2002 in China. Parainfluenza virus is the cause of the laryngeal croup in infants.
RESUMO
No disponible
Assuntos
Masculino , Idoso , Humanos , Adenocarcinoma/patologia , Neoplasias da Próstata/patologia , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/secundário , Tomografia Computadorizada por Raios XRESUMO
Coexistence of a vasculitis and a neoplastic disease is rare and the pathogenesis is unknown. Most of these associations refer to leukocytoclastic or poliarteritis nodosa (PAN)-type vasculitis and hematological malignancies. There are few reports of vasculitis in patients with solid tumours and there are also few reports of paraneoplastic ANCA-associated vasculitis. We report a case of p-ANCA-positive vasculitis with peripheral nerve involvement associated with a colon cancer. Vasculitis resolved after corticoid treatment and surgical removal of the tumour.
Assuntos
Adenocarcinoma/complicações , Anticorpos Anticitoplasma de Neutrófilos/sangue , Neoplasias do Colo/complicações , Síndromes Paraneoplásicas/etiologia , Vasculite/etiologia , Adenocarcinoma/sangue , Neoplasias do Colo/sangue , Feminino , Humanos , Pessoa de Meia-Idade , Síndromes Paraneoplásicas/sangue , Vasculite/sangueRESUMO
No disponible